Heidari Horestani M, Atri Roozbahani G, Baniahmad A
Cancers (Basel). 2025; 17(5).
PMID: 40075640
PMC: 11898987.
DOI: 10.3390/cancers17050791.
Ishii K, Iguchi K, Matsuda C, Hirokawa Y, Sugimura Y, Watanabe M
J Clin Med. 2025; 13(24.
PMID: 39768760
PMC: 11678552.
DOI: 10.3390/jcm13247837.
Dutta S, Khedmatgozar H, Patel G, Latour D, Welsh J, Mustafi M
Oncogene. 2024; .
PMID: 39702503
DOI: 10.1038/s41388-024-03252-5.
Corres-Mendizabal J, Zacchi F, Martin-Martin N, Mateo J, Carracedo A
Trends Cancer. 2024; 10(9):825-841.
PMID: 39048488
PMC: 11397905.
DOI: 10.1016/j.trecan.2024.06.005.
Kurganovs N, Engedal N
Front Pharmacol. 2024; 15:1419806.
PMID: 38910881
PMC: 11190189.
DOI: 10.3389/fphar.2024.1419806.
The clock gene BHLHE40 and atypical CCNG2 control androgen-induced cellular senescence as a novel tumor suppressive pathway in prostate cancer.
Heidari Horestani M, Atri Roozbahani G, Baniahmad A
J Exp Clin Cancer Res. 2024; 43(1):174.
PMID: 38902772
PMC: 11188219.
DOI: 10.1186/s13046-024-03097-6.
Therapeutic Effects of Essential Oils and Their Bioactive Compounds on Prostate Cancer Treatment.
Pimentel L, Bastos L, Goulart L, Ribeiro L
Pharmaceutics. 2024; 16(5).
PMID: 38794244
PMC: 11125265.
DOI: 10.3390/pharmaceutics16050583.
Combination of miR-99b-5p and Enzalutamide or Abiraterone Synergizes the Suppression of EMT-Mediated Metastasis in Prostate Cancer.
Waseem M, Wang B
Cancers (Basel). 2024; 16(10).
PMID: 38792011
PMC: 11119738.
DOI: 10.3390/cancers16101933.
Engineered CRISPR-Cas12a for higher-order combinatorial chromatin perturbations.
Hsiung C, Wilson C, Sambold N, Dai R, Chen Q, Teyssier N
Nat Biotechnol. 2024; .
PMID: 38760567
DOI: 10.1038/s41587-024-02224-0.
Spontaneous Fusion with Transformed Mesenchymal Stromal Cells Results in Complete Heterogeneity in Prostate Cancer Cells.
Wang R, Hu P, Wang F, Lyu J, Ou Y, Edderkaoui M
Cancers (Basel). 2024; 16(5).
PMID: 38473313
PMC: 10931070.
DOI: 10.3390/cancers16050951.
CYP19A1 is downregulated by BRD4 and suppresses castration-resistant prostate cancer cell invasion and proliferation by decreasing AR expression.
Chen X, Li H, Xu C, Wang X, Wu G, Li C
Am J Cancer Res. 2023; 13(9):4003-4020.
PMID: 37818065
PMC: 10560923.
Discordant interactions between YAP1 and polycomb group protein SCML2 determine cell fate.
Boston A, Dwead A, Al-Mathkour M, Khazaw K, Zou J, Zhang Q
iScience. 2023; 26(10):107964.
PMID: 37810219
PMC: 10558808.
DOI: 10.1016/j.isci.2023.107964.
A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer.
Mourkioti I, Polyzou A, Veroutis D, Theocharous G, Lagopati N, Gentile E
J Exp Clin Cancer Res. 2023; 42(1):187.
PMID: 37507762
PMC: 10386253.
DOI: 10.1186/s13046-023-02769-z.
Switching mechanism from AR to EGFR signaling via 3-O-sulfated heparan sulfate in castration-resistant prostate cancer.
Ota H, Sato H, Mizumoto S, Wakai K, Yoneda K, Yamamoto K
Sci Rep. 2023; 13(1):11618.
PMID: 37463954
PMC: 10354070.
DOI: 10.1038/s41598-023-38746-x.
Cleavage of the V-ATPase associated prorenin receptor is mediated by PACE4 and is essential for growth of prostate cancer cells.
Mohammad A, Couture F, Gamache I, Chen O, El-Assaad W, Abdel-Malak N
PLoS One. 2023; 18(7):e0288622.
PMID: 37463144
PMC: 10353799.
DOI: 10.1371/journal.pone.0288622.
Osteoblast-derived extracellular vesicles exert osteoblastic and tumor-suppressive functions via SERPINA3 and LCN2 in prostate cancer.
Ito K, Yamamoto T, Hayashi Y, Sato S, Nakayama J, Urabe F
Mol Oncol. 2023; 17(10):2147-2167.
PMID: 37408474
PMC: 10552899.
DOI: 10.1002/1878-0261.13484.
Animal models of bone metastatic prostate cancer.
Tae J, Chang I
Investig Clin Urol. 2023; 64(3):219-228.
PMID: 37341002
PMC: 10172043.
DOI: 10.4111/icu.20230026.
Trends in Subcutaneous Tumour Height and Impact on Measurement Accuracy.
Brough D, Amos H, Turley K, Murkin J
Cancer Inform. 2023; 22:11769351231165181.
PMID: 37113645
PMC: 10126793.
DOI: 10.1177/11769351231165181.
Bone marrow niche chemoprotection of metastatic solid tumors mediated by CYP3A4.
Ghiaur G, Valkenburg K, Esteb C, Ambinder A, Imus P, Pienta K
Cancer. 2023; 129(11):1744-1751.
PMID: 36840972
PMC: 10966383.
DOI: 10.1002/cncr.34704.
Preclinical models of prostate cancer - modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo.
Germain L, Lafront C, Paquette V, Neveu B, Paquette J, Pouliot F
Nat Rev Urol. 2023; 20(8):480-493.
PMID: 36788359
DOI: 10.1038/s41585-023-00726-1.